IO102-IO103 in Combination With Pembrolizumab as First-line Treatment for Patients With Metastatic NSCLC, SCCHN, or mUBC

Clinical trial NCT05077709 · COMPLETED

Trial details

NCT number: NCT05077709
Sponsor: IO Biotech
Status: COMPLETED
Phase: Phase 2
Study type: INTERVENTIONAL

Lung Cancer Non Small Cell Head and Neck Squamous Cell Carcinoma Urothelial Carcinoma Bladder

Start date: 2022-04-11
Primary completion: 2025-11-30
Enrollment: 63

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.